We are excited to share our new paper in @ScienceTM describing UBE2N as a novel therapeutic target in #AML. science.org/doi/epdf/10.11…
Daniel Starczynowski
1,285 posts
Daniel Starczynowski
@dstarczynowski
Professor at Cincinnati Children’s Hospital. Cancer biologist focused on hematologic malignancies (#MDS and #AML). Views my own.
Joined December 2012
- Thrilled to share our new story in @CellStemCell - a tour de force team effort spearheaded by @tchlon. He identified that DDX41 mutations contribute to MDS through discrete mechanisms in monoallelic and biallelic mutant clones.
- We are excited to share our new paper in @Haematologica describing the complex relationship between #inflammation, #p53, and #MDS. Congrats to lead author Tomoya Muto for spearheading the project. haematologica.org/article/view/h…
- We are excited to share our new story @NatImmunol on how an adaptation of MDS HSPCs to inflammation contributes to a competitive advantage. Congrats to Tomoya Muto and the awesome team @garciamanero @MDAndersonNews @UCSF @CincyChildrens @LLSResearch. rdcu.be/b3FHz
- Very proud that our lab was awarded the highest level of certification by @My_Green_Lab - the 1st at @CincyChildrens and in #Ohio! The #GreenLabCertification is the gold standard in lab sustainability practices. Huge thanks to Lyndsey Bolanos and our “sustainability champions”!
- We are excited to share our latest paper in @BloodJournal describing new functions of the IRAK1 & IRAK4 complex in MDS/AML, which has broad therapeutic implications. ashpublications.org/blood/article/…
- Congrats to Tomoya and Maria (@Maguillamot) on their new story in @CellStemCell - a tour de force team effort between the Starczynowski and @iannisaifantis1 labs on a new tumor suppressor role of TRAF6 in #AML by targeting MYC activity: authors.elsevier.com/a/1eRRY6tu0CeT…
- Excited to share our @JExpMed perspective on the emerging role of innate immune signaling dysregulation in hematopoietic aging, clonal hematopoiesis, and MDS. Huge thanks to the @TrowbridgeLab and @dstarczynowski lab members! rupress.org/jem/article/21…
- Join us for the rescheduled but equally exciting Virtual Keystone Symposia April 21-23 2021 on the latest research in normal and malignant hematopoiesis. #VKSHemato21
- We are excited to share our latest paper in @iScience describing the complex role of dysregulated innate/inflammatory signaling in the progression of #MDS to #AML with RUNX1 mutations. sciencedirect.com/science/articl…
- Congrats @Maddie_Science! It is a bitter sweet day as it is her last day in the lab after a widely successful PhD. She is embarking on her postdoc with John Crispino @StJudeResearch. Maddie is a science rockstar and an awesome colleague! We will all miss her @CincyChildrens.
- If you are interested in how inflammation can impact #MDS, check out our new pre-print in @biorxivpreprint: Chronic inflammation suppresses del(5q)-like MDS HSCs via p53
- Happy to see the final version of our paper in the latest edition of @BloodJournal. In this paper, we describe new functions of the IRAK1 & IRAK4 complex in myeloid malignancies, shedding light on its therapeutic implications.We are excited to share our latest paper in @BloodJournal describing new functions of the IRAK1 & IRAK4 complex in MDS/AML, which has broad therapeutic implications. ashpublications.org/blood/article/…ashpublications.orgParalog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AMLKey Points. Cotargeting of IRAK1 and IRAK4 is required to maximally suppress LSPC function in vitro and in vivo by inducing cellular differentiation.The de
- Join us for the Keystone Hematopoiesis eSymposia April 21-23 2021. Deadline for short talks is March 10. Priority will be given to trainees and junior faculty. Email or DM if you have questions. #VKSHemato21
